George Kemble Sells 20,206 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock

Sagimet Biosciences Inc. (NASDAQ:SGMT) Director George Kemble sold 20,206 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total transaction of $201,049.70. Following the transaction, the director owned 62,161 shares in the company, valued at approximately $618,501.95. This trade represents a 24.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

George Kemble also recently made the following trade(s):

• On Monday, July 20th, George Kemble sold 18,844 shares of Sagimet Biosciences stock. The shares were sold at an average price of $7.46, for a total transaction of $140,576.24.

Sagimet Biosciences Price Performance

SGMT stock opened at $9.28 on Friday. The company has a market cap of $302.34 million, a price-to-earnings ratio of -7.25 and a beta of 3.37. The company has a fifty day moving average price of $7.44 and a 200 day moving average price of $6.54. Sagimet Biosciences Inc. has a 12 month low of $4.50 and a 12 month high of $10.01.

Sagimet Biosciences (NASDAQ:SGMT) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). As a group, analysts anticipate that Sagimet Biosciences Inc. will post -1.17 earnings per share for the current year.

Key Sagimet Biosciences News

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne trial: The FDA issued a “Study May Proceed” letter and cleared Sagimet’s IND application for a U.S. Phase 3 trial of denifanstat in moderate to severe acne. The study is expected to begin in the second half of 2026 and enroll approximately 800 patients, including about 450 adolescents. This removes a key regulatory hurdle and advances denifanstat toward a potential commercial opportunity. FDA Phase 3 trial clearance
• Positive Sentiment: Analyst remains bullish: Canaccord Genuity raised its price target for SGMT from $49 to $56 and maintained a “buy” rating, reflecting confidence in denifanstat’s development potential. Wedbush also described Sagimet as making good progress toward bringing the drug to U.S. patients. Canaccord price target Wedbush commentary
• Neutral Sentiment: Clinical and funding risks remain: The Phase 3 trial will require successful enrollment, efficacy and safety results, and additional development spending. Prior positive data came from Sagimet’s license partner, Ascletis, in China and may not fully predict outcomes in U.S. patients.
• Negative Sentiment: Director sells shares: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. Although insider sales can be routine, the transaction may weigh on sentiment. George Kemble insider sale
• Negative Sentiment: Loss estimates lowered: HC Wainwright cut its fourth-quarter 2026 EPS forecast to a loss of $0.32 from $0.30. Sagimet also recently reported a quarterly loss of $0.26 per share, slightly worse than consensus.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SGMT. Bank of New York Mellon Corp acquired a new stake in Sagimet Biosciences in the second quarter valued at about $1,551,000. Bank of America Corp DE raised its stake in shares of Sagimet Biosciences by 344.1% during the 1st quarter. Bank of America Corp DE now owns 43,858 shares of the company’s stock worth $229,000 after buying an additional 33,982 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Sagimet Biosciences by 82.6% during the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock worth $3,268,000 after buying an additional 282,969 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Sagimet Biosciences by 99.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock valued at $1,415,000 after buying an additional 135,178 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Sagimet Biosciences in the 4th quarter valued at approximately $62,000. 87.86% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on SGMT. Canaccord Genuity Group upped their price objective on Sagimet Biosciences from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Friday, July 17th. Oppenheimer reissued an “outperform” rating on shares of Sagimet Biosciences in a report on Friday, May 1st. Citizens Jmp cut their price target on Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating for the company in a research note on Tuesday, May 19th. Finally, Guggenheim decreased their price target on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Sagimet Biosciences has an average rating of “Moderate Buy” and an average target price of $26.33.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.